The Parkinson's-Reversing Breakthrough

What is Parkinsons Disease

Get Instant Access

1. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005; 353(10):1021-1027.

2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24(2): 197-211.

3. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 2002; 17(3):501-508.

4. Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 2002; 23(1-3):65-70.

5. Funk C. Synthase des d, 1-3-4, dioxyphenalanins. Chem Zenttralbl I 1911.

6. Guggenhiem M. Dioxyphenlalanin, eine neue Aminosarue aus Vicia faba. Z Phy Chem 1913.

7. Carlsson A, Lindqvist M, Magmusson T. 3,4 - dihydroxyphenylalanine and 5-hydrox-ytriptophan as reserpine antagonists. Nature (London) 1957; 180:1200.

8. Carlsson A, Linqvist M, Magmusson T, Waldbeck B. On the presence of 3-hydroxytyramine in the brain. Science 1958; 127(471).

9. Ehringer H, Hornykiewicz O. Verteilung von noradrenalin und dopamin im gehirn des menschwen und ihr verhalten bei erkrankingen des extrapyramidalen systems. Klin Wochensher 1960; 38:1236-1239.

10. Barbeau A, Murphy GF, Sourkes TL. Excretion of dopamine in diseases of basal ganglia. Science 1961; 133:1706-1707.

11. Cotzias GC, Van Woert M, Shiffer L. Aromatic amino acides and modification of parkinsonism. N Engl J Med 1967; 276:374-379.

12. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism-chronic treatment with L-DOPA. N Engl J Med 1969; 280:337-345.

13. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21(4):343-354.

14. Kapp W. The hisotory of drugs for the treatment of Parkinson's disease. J Neural Transm 1992; 38:1-6.

15. Rinne UK, Molsa P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology 1979; 29(12):1584-1589.

16. Rinne UK, Birket-Smith E, Dupont E, et al. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial. J Neurol 1975; 211(1):1-9.

17. Goetz CG, Tanner CM, Shannon KM, et al. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology 1988; 38(7):1143-1146.

18. Jankovic J, Schwartz K, Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord 1989; 4(4):303-309.

19. Factor SA, Sanchez-Ramos JR, Weiner WJ, Ingenito AM. Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1989; 52(1): 83-88.

20. Factor SA. Parkinson's disease: initial treatment with levodopa or dopamine agonists. Curr Treat Options Neurol 2001; 3(6):479-493.

21. Jorga KM. COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin Neuropharmacol 1998; 21(suppl 1):S9-S16.

22. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984; 310(8):483-488.

23. Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980; 8(6):558-563.

24. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20(4):415-455.

25. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 1987; 22(4):475-479.

26. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990; 525(1):36-44.

27. Poewe W. Clinical and pathophysiologic aspects of late levodopa failure. Neurology 1993; 43(12 suppl 6):S28-S30.

28. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987; 2(2):73-91.

29. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16(3):448-458.

30. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971; 46(4):231-239.

31. Nutt JG, Carter JH. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD. Neurology 2000; 54(1):247-250.

32. Nutt JG, Carter JH, Woodward WR. Long-duration response to levodopa. Neurology 1995; 45(8):1613-1616.

33. Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2001; 8(2):101-108.

34. Nutt JG. Pharmacodynamics of levodopa in Parkinson's disease. Clin Exp Pharmacol Physiol 1995; 22(11):837-840.

35. Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988; 38(10):1553-1557.

36. Merello M, Hughes A, Colosimo C, Hoffman M, Starkstein S, Leiguarda R. Sleep benefit in Parkinson's disease. Mov Disord 1997; 12(4):506-508.

37. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to l-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977; 52(3):163-174.

38. Fahn S. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 1974; 24(5):431-441.

39. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1(7954):292-296.

40. Factor SA. Parkinson's disease: motor fluctuations. Curr Treat Options Neurol 1999; 1(1):21-32.

41. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000; 47(4 suppl 1):S2-S9.

42. Muenter MD. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease. Neurology 1970; 20(suppl 12):6-13.

43. McDowell FH, Markham CH, Lee JE, Treciokas LJ, Ansel RD. The clinical use of levodopa in the treatment of Parkinson's disease. Contemp Neurol Ser 1971; 8:175-201.

44. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; 1(8007):345-349.

45. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med 1975; 83(4):456-463.

46. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984; 34(8):991-996.

47. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986; 36(11):1528-1530.

48. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Lev-odopa Study Group. Neurology 1999; 53(5):1012-1019.

49. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61(7): 1044-1053.

50. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 2000; 284(15):1931-1938.

51. Group PS. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287(13):1653-1661.

52. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342(20):1484-1491.

53. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54(1):93-101.

54. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 2006; 21:343-353.

55. Morrish P. Is it time to abandon functional imaging in the study of neuroprotection? Mov Disord 2002; 17(2):229-232.

56. Morrish PK. REAL and CALM: what have we learned? Mov Disord 2003; 18(7):839-840.

57. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001; 56(11): 1559-1564.

58. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64(2):208-215.

59. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351(24):2498-2508.

60. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005; 252(suppl 4):iv37-iv42.

61. Barbeau A. Editorial: long-term assessment of levodopa therapy in Parkinson's disease. Can Med Assoc J 1975; 112(12):1379-1380.

62. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979; 29(9 Pt 1):1253-1260.

63. de Jong GJ, Meerwaldt JD, Schmitz PI. Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 1987; 22(1):4-7.

64. Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991; 41(5):622-629.

65. Blin J, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988; 38(9):1410-1416.

66. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991; 41(3):380-384.

67. Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983; 19:253-264.

68. Horstink MW, Zijlmans JC, Pasman JW, Berger HJ, van't Hof MA. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990; 53(3):224-226.

69. Roos RA, Vredevoogd CB, van der Velde EA. Response fluctuations in Parkinson's disease. Neurology 1990; 40(9):1344-1346.

70. Kostic VS, Marinkovic J, Svetel M, Stefanova E, Przedborski S. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 2002; 9(1):9-14.

71. Onofrj M, Paci C, Thomas A. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 65(4):605-606.

72. Langston JW. The impact of Parkinson's disease research: past, present and future. In: Factor SA, Weiner WJ, eds. Parkinson's Disease: Diagnosis and Clinical Management. New York: Demos, 2002:299-329.

73. Fahn S. Welcome news about levodopa, but uncertainty remains. Ann Neurol 1998; 43(5):551-554.

74. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988; 24(3):366-371.

75. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36(1):27-31.

76. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neu-rol 1988; 24(3):372-378.

77. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19(9):997-1005.

78. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 2003; 14(3):404-416.

79. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005; 62(6):905-910.

80. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monother-apy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64(2): 216-223.

81. Nutt JG, Carter JH, Lea ES, Woodward WR. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 1997; 12(3):285-292.

82. Syed N, Murphy J, Zimmerman T Jr, Mark MH, Sage JI. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998; 13(2):336-338.

83. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990; 27(1):18-23.

84. Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986; 43(4):402-405.

85. Shulman LM. Levodopa toxicity in Parkinson disease: reality or myth? Reality—practice patterns should change. Arch Neurol 2000; 57(3):406-407; discussion 410.

86. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005; 20(3):342-344.

Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32(6):804-812.

Blandini F, Mangiagalli A, Cosentino M, et al. Peripheral markers of apoptosis in Parkinson's disease: the effect of dopaminergic drugs. Ann NY Acad Sci 2003; 1010: 675-678.

Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990; 40(10 suppl 3):suppl 32-37; discussion 37-39.

Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord 2005; 20(3):271-282.

Calne DB. The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann Neurol 1992; 32(6):799-803.

Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 1999; 14(6):911-913.

Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998; 351(9106):851-852. Agid Y. Levodopa: is toxicity a myth? Neurology 1998; 50(4):858-863. Fahn S. Is levodopa toxic? Neurology 1996; 47(6 suppl 3):S184-S195. Olney JW, Zorumski CF, Stewart GR, Price MT, Wang GJ, Labruyere J. Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases. Exp Neurol 1990; 108(3):269-272.

Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993; 34(5):715-723. Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E. Levodopa induces apoptosis in cultured neuronal cells—a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 1997; 12(1):17-23.

Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993; 61(4):1470-1478.

Mena MA, Pardo B, Casarejos MJ, Fahn S, Garcia de Yebenes J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992; 7(1):23-31. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997; 69(4):1398-1408. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of levodopa does not damage dopaminergic neurons in the mouse. Neurology 1981; 31:1195-1195. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984; 43(4):990-993.

Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 2003; 304(2):792-800.

Lyras L, Zeng BY, McKenzie G, Pearce RK, Halliwell B, Jenner P. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 2002; 109(1):53-67.

Pearce RK, Heikkila M, Linden IB, Jenner P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology (Berl) 2001; 156(4):402-409.

Cotzias GC, Miller ST, Tang LC, Papavasiliou PS. Levodopa, fertility, and longevity. Science 1977; 196(4289):549-551.

Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993; 8(2):129-133.

Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43(5):561-575.

Fukuda T, Watabe K, Tanaka J. Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res 1996; 728(2):274-276. Datla KP, Blunt SB, Dexter DT. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their func-

tional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 2001; 16(3):424-434.

112. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986; 1(1):65-68.

113. Rajput AH, Fenton M, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997; 12(5):634-638.

114. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001; 8(2):95-100.

115. Yahr MD, Wolf A, Antunes JL, et al. Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1972; 22(suppl):56-71.

116. Gwinn-Hardy K, Evidente VG, Waters C, Muenter MD, Hardy J. L-dopa slows the progression of familial parkinsonism. Lancet 1999; 353(9167):1850-1851.

117. Pfutzner W, Przybilla B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol 1997; 37(2 Pt 2): 332-336.

118. Woofter MJ, Manyam BV. Safety of long-term levodopa therapy in malignant melanoma. Clin Neuropharmacol 1994; 17(4):315-319.

119. Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol 1986; 19(4):365-372.

120. Markham CH, Diamond SG. Evidence to support early levodopa therapy in Parkinson disease. Neurology 1981; 31(2):125-131.

121. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20(2): 190-199.

122. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17(5):427-442.

123. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987; 22(1):8-12.

124. Scigliano G, Musicco M, Soliveri P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 1990; 40(2):265-269.

125. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993; 43(10):1918-1926.

126. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord 2003; 9(6):321-327.

127. Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN. Levodopa, melanoma, and Parkinson's disease. Neurology 1993; 43(4):674-677.

128. Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK. Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 2000; 34(3):382-385.

129. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonsim Relat Disord 2003; 9:321-327.

130. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005; 92(1):201-205.

131. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004; 63(5):886-891.

132. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288(16): 2023-2031.

133. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002; 59(4):529-536.

134. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346(7):476-483.

135. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperho-mocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003; 108(1):66-67.

136. O'Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004; 19(12):1403-1408.

137. Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 2001; 161(5):695-700.

138. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003; 60(1):59-64.

139. Bostantjopoulou S, Katsarou Z, Frangia T, et al. Endothelial function markers in parkinsonian patients with hyperhomocysteinemia. J Clin Neurosci 2005; 12(6):669-672.

140. Zoccolella S, Lamberti P, Iliceto G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005; 43(10):1107-1110.

141. Zoccolella S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 2005; 11(2):131-133.

142. Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005; 20(1):69-72.

143. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005; 11:253-256.

144. Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 2005; 118(11):1250-1255.

145. Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69(5):590-594.

146. Rossi P, Colosimo C, Moro E, Tonali P, Albanese A. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol 2000; 43(2):95-101.

Was this article helpful?

0 0
Anti Aging Made Easy

Anti Aging Made Easy

When it comes to reducing wrinkles, you really have to take your needs seriously. There are a number of factors that play a role in the health and well being of your skin. It is often hard to understand how products work and why they may not work even if they promise to do so. If you are considering wrinkle creams and a regimen of facelifts, you may go broke in the process. Before you do all of that, consider going through a process of determine the very best solution for your needs.

Get My Free Ebook

Post a comment